 | Up a level |
Passaro, A. and Wang, J. and Wang, Y. and Lee, S. -H. and Melosky, B. and Shih, J. -Y. and Wang, J. and Azuma, K. and Juan-Vidal, O. and Cobo, M. and Felip, E. and Girard, N. and Cortot, A. B. and Califano, R. and Cappuzzo, F. and Owen, S. and Popat, S. and Tan, J. -l. and Salinas, J. and Tomasini, P. and Gentzler, R. D. and William, W. N. and Reckamp, K. L. and Takahashi, T. and Ganguly, S. and Kowalski, D. M. and Bearz, A. and MacKean, M. and Barala, P. and Bourla, A. B. and Girvin, A. and Greger, J. and Millington, D. and Withelder, M. and Xie, J. and Sun, T. and Shah, S. and Diorio, B. and Knoblauch, R. E. and Bauml, J. M. and Campelo, R. G. and Cho, B. C. and Investigators, MARIPOSA-2 (2024) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Annals of Oncology, 35 (1). ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2023.10.117.
